BRAF Biomarkers
Servier Licenses Black Diamond Therapeutics' RAF-Targeted Solid Tumor Candidate
In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.
FDA Approves Pfizer's Braftovi With Eli Lilly's Erbitux, Chemo in Colorectal Cancer
The agency granted accelerated approval to the regimen as a frontline option for advanced, BRAF V600E-mtuated tumors based on the BREAKWATER trial.
Boundless Bio Ends Trial of BBI-825 in Patients With Certain Cancer Resistance Mutations
Due to unfavorable pharmacokinetics and the development costs of BRAF V600E and KRAS G12C mutated cancers, the firm will not advance the STARMAP trial.
Tizona Therapeutics Expands Phase Ib Trial to Include Biomarker-Selected Colorectal Cancer Cohorts
In the new arms, patients with certain biomarker-defined tumors will receive either an HLA-G targeted antibody, chemo, and Erbitux, or just chemo and Erbitux.
Braftovi, Mektovi Approved in Europe for BRAF V600E-Mutant NSCLC
A Phase II trial of the combo demonstrated response rates of 75 percent and 46 percent in treatment-naïve and previously treated NSCLC patients, respectively.